JP2011513317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513317A5 JP2011513317A5 JP2010548820A JP2010548820A JP2011513317A5 JP 2011513317 A5 JP2011513317 A5 JP 2011513317A5 JP 2010548820 A JP2010548820 A JP 2010548820A JP 2010548820 A JP2010548820 A JP 2010548820A JP 2011513317 A5 JP2011513317 A5 JP 2011513317A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- group
- hydrogen
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 272
- 229910052739 hydrogen Inorganic materials 0.000 claims description 77
- 239000001257 hydrogen Substances 0.000 claims description 70
- -1 6 -Naphthyl Chemical group 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 45
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 38
- 150000002431 hydrogen Chemical class 0.000 claims description 38
- 229910052736 halogen Inorganic materials 0.000 claims description 34
- 150000002367 halogens Chemical class 0.000 claims description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 32
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 29
- 238000009472 formulation Methods 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 27
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 claims description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 16
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 12
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 12
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 12
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 229920000728 polyester Polymers 0.000 claims description 12
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 12
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 12
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000001624 naphthyl group Chemical group 0.000 claims description 10
- 125000003003 spiro group Chemical group 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 8
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 8
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 8
- 229960002216 methylparaben Drugs 0.000 claims description 8
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 8
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 8
- 229960004063 propylene glycol Drugs 0.000 claims description 8
- 229960003415 propylparaben Drugs 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 229960000541 cetyl alcohol Drugs 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 239000002480 mineral oil Substances 0.000 claims description 6
- 235000010446 mineral oil Nutrition 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- 239000004599 antimicrobial Substances 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 5
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 claims description 4
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 claims description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 4
- 239000003380 propellant Substances 0.000 claims description 4
- 235000013772 propylene glycol Nutrition 0.000 claims description 4
- 229940093625 propylene glycol monostearate Drugs 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 229940042129 topical gel Drugs 0.000 claims description 4
- 229940044959 vaginal cream Drugs 0.000 claims description 4
- 239000000522 vaginal cream Substances 0.000 claims description 4
- 229940044950 vaginal gel Drugs 0.000 claims description 4
- 239000000029 vaginal gel Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000001993 wax Substances 0.000 claims description 4
- 229940045860 white wax Drugs 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 230000005540 biological transmission Effects 0.000 claims description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- PWVUXRBUUYZMKM-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCO PWVUXRBUUYZMKM-UHFFFAOYSA-N 0.000 claims description 2
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 239000004166 Lanolin Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical group COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 229940107161 cholesterol Drugs 0.000 claims description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 229940031768 diglycol stearate Drugs 0.000 claims description 2
- 239000008387 emulsifying waxe Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 229940075529 glyceryl stearate Drugs 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 235000019388 lanolin Nutrition 0.000 claims description 2
- 229940039717 lanolin Drugs 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 239000004200 microcrystalline wax Substances 0.000 claims description 2
- 235000019808 microcrystalline wax Nutrition 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229940049964 oleate Drugs 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 claims description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000001294 propane Substances 0.000 claims description 2
- 229940096976 rectal foam Drugs 0.000 claims description 2
- 229940041666 rectal gel Drugs 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 229940083608 sodium hydroxide Drugs 0.000 claims description 2
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 229940100515 sorbitan Drugs 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 229940100611 topical cream Drugs 0.000 claims description 2
- 229940042130 topical foam Drugs 0.000 claims description 2
- 229940100617 topical lotion Drugs 0.000 claims description 2
- 229940100615 topical ointment Drugs 0.000 claims description 2
- 229960004418 trolamine Drugs 0.000 claims description 2
- 229940044952 vaginal foam Drugs 0.000 claims description 2
- 239000000259 vaginal foam Substances 0.000 claims description 2
- 239000006213 vaginal ring Substances 0.000 claims description 2
- 229940044953 vaginal ring Drugs 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 0 CC(*)(*)c1ccccc1 Chemical compound CC(*)(*)c1ccccc1 0.000 description 1
- GHPODDMCSOYWNE-UHFFFAOYSA-N Cc(cc1)cc2c1OCO2 Chemical compound Cc(cc1)cc2c1OCO2 GHPODDMCSOYWNE-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3253908P | 2008-02-29 | 2008-02-29 | |
| PCT/US2009/034990 WO2009111218A2 (en) | 2008-02-29 | 2009-02-24 | Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011513317A JP2011513317A (ja) | 2011-04-28 |
| JP2011513317A5 true JP2011513317A5 (https=) | 2013-03-14 |
Family
ID=40627290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010548820A Pending JP2011513317A (ja) | 2008-02-29 | 2009-02-24 | Ｈｉｖ感染を防止するための予防薬としてのｃｃｒ５アンタゴニストおよびｈｉｖの伝播を抑制する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110059154A1 (https=) |
| EP (1) | EP2259772A2 (https=) |
| JP (1) | JP2011513317A (https=) |
| AU (1) | AU2009220462A1 (https=) |
| CA (1) | CA2716838C (https=) |
| WO (1) | WO2009111218A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
| DE102012209008B4 (de) | 2012-05-29 | 2015-02-05 | Wellcomet Gmbh | Vorrichtung zum Erzeugen von Behandlungswellen |
| US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
| CN104997725B (zh) * | 2015-07-13 | 2017-10-20 | 山西锦波生物医药股份有限公司 | 抗hiv病毒的马来酸b07凝胶制剂配方及制备方法 |
| EP3370701A1 (en) | 2015-11-06 | 2018-09-12 | INEB-Instituto Nacional De Engenharia Biomédica | A composition for use in a method for prevention or treatment of human immunodeficiency virus infections |
| JP7512010B2 (ja) * | 2018-09-20 | 2024-07-08 | 株式会社ヤクルト本社 | 経皮吸収用組成物及び経皮吸収性向上方法 |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050276836A1 (en) * | 1997-06-11 | 2005-12-15 | Michelle Wilson | Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents |
| CA2371583C (en) * | 1999-05-04 | 2005-09-13 | Schering Corporation | Piperazine derivatives useful as ccr5 antagonists |
| US6387930B1 (en) * | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| HK1039330B (en) * | 1999-05-04 | 2005-12-09 | Schering Corporation | Piperidine derivatives useful as ccr5 antagonists |
| US6391865B1 (en) * | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| RS50904B (sr) * | 2000-05-26 | 2010-08-31 | Pfizer Inc. | Derivati tropana i njihova primena |
| PL364560A1 (en) * | 2001-03-29 | 2004-12-13 | Schering Corporation | Ccr5 antagonists useful for treating aids |
| US8178123B2 (en) * | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| UA93354C2 (ru) * | 2004-07-09 | 2011-02-10 | Гилиад Сайенсиз, Инк. | Местный противовирусный препарат |
| AR052865A1 (es) * | 2005-01-06 | 2007-04-11 | Schering Corp | Preparacion de compuestos farmaceuticos derivados de sales de piperazina |
| WO2007033208A2 (en) * | 2005-09-12 | 2007-03-22 | University Of Maryland Biotechnology Institute Off. Of Research Admin/Tech. Dev. | Use of indirubin and its derivatives in the treatments of hiv infection and heart failure |
| EP1948103A2 (en) * | 2005-09-15 | 2008-07-30 | UMD, Inc. | A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration |
| TW200745087A (en) * | 2006-02-24 | 2007-12-16 | Schering Corp | CCR5 antagonists useful for treating HIV |
-
2009
- 2009-02-24 EP EP09716758A patent/EP2259772A2/en not_active Withdrawn
- 2009-02-24 CA CA2716838A patent/CA2716838C/en not_active Expired - Fee Related
- 2009-02-24 AU AU2009220462A patent/AU2009220462A1/en not_active Abandoned
- 2009-02-24 WO PCT/US2009/034990 patent/WO2009111218A2/en not_active Ceased
- 2009-02-24 US US12/919,833 patent/US20110059154A1/en not_active Abandoned
- 2009-02-24 JP JP2010548820A patent/JP2011513317A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011513317A5 (https=) | ||
| US20100099766A1 (en) | Topical NSAID compositions having sensate component | |
| JP2006528700A5 (https=) | ||
| CN112423750A (zh) | 用于治疗hiv的衣壳抑制剂 | |
| WO2009100406A2 (en) | Topical formulations for the treatment of psoriasis | |
| RU2001132632A (ru) | Производные пиперазина, применимые в качестве антагонистов CCR5 | |
| US20040014761A1 (en) | Treatment of female sexual dysfunction with phosphodiesterase inhibitors | |
| JP2007531740A5 (https=) | ||
| JP2002510329A (ja) | 親油性化合物用の自己乳化性処方 | |
| JP2003525894A5 (https=) | ||
| JP2012525437A5 (https=) | ||
| WO2014129495A1 (ja) | 眼疾患処置薬 | |
| JP2002542298A5 (https=) | ||
| JP2005514358A5 (https=) | ||
| US20140357600A1 (en) | Novel ester containing compositions and methods | |
| US6365590B1 (en) | Compounds, compositions and methods for treating erectile dysfunction | |
| US20220142981A1 (en) | Apremilast lipophilic topical pharmaceutical compositions | |
| JP2010533707A5 (https=) | ||
| AU2005210660A1 (en) | Antiparasitic composition containing an organic amine salt of closantel | |
| CN112300099A (zh) | 药物的缩酮衍生物及其制备方法、药物组合物和用途 | |
| JPH02233613A (ja) | ピペリジノアルカノール誘導体類用の液体製剤組成物 | |
| JPWO2023114937A5 (https=) | ||
| CA2580910A1 (en) | Pharmaceutical composition comprising temozolomide ester | |
| JP2011509237A5 (https=) | ||
| WO2002004012A1 (en) | Anhydrous pharmaceutical composition of vancomycin for topical use |